AR and posterior cortical atrophy: Current treatment strategies for mCRPC patients have been developed, such as androgen receptor inhibitors, PARP inhibitors, and prostate-specific membrane antigen (PSMA)-targeting therapies [31], and there is still considerable room to improve the treatment efficacy and find new drugs for PCa treatment.